A Phase 2 interventional study of gemcitabine and paclitaxel in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 50th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2006, is one of 65 in phase 2, and was the 41st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 64th largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2006, is one of 41 in phase 2, and was the 28th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the response rate to a gemcitabine-paclitaxel combination administered on a 3-weekly schedule in Chinese patients with unresectable, locally recurrent breast cancer or metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gemcitabine · Drug: paclitaxel
1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
Also known as: LY188011, Gemzar
175 mg/m2, intravenous (IV), every 21 days until disease progression
Best Overall Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Time frame: baseline to measured progressive disease (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)
Time to Treatment Failure
Defined as time from enrollment to the date of death due to any cause, measured disease progression, treatment discontinuation for undocumented progression, early treatment discontinuation for toxicity or other reason, or new anticancer treatment started.
Time frame: baseline to stopping treatment
Progression-Free Survival
Defined as the time from enrollment to the date of objective disease progression or death on study, whichever occurs first. Censoring was determined based on US-FDA 2005 draft guidance on clinical endpoints.
Time frame: baseline to measured progressive disease or death (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)
Duration of Response
Measured from the time of first documentation of complete response (CR) or partial response (PR), whichever status is first recorded, until the date of objective disease progression or death on study, whichever occurs first, with censoring defined in the same way as for progression-free survival.
Time frame: time of response to measured progressive disease or death (tumor assessments were performed every 2 cycles during study therapy, or 3 months during post-therapy until disease progression, or up to 12 months after enrollment)
Overall Survival Probability
Original outcome was overall survival = time from date of enrollment to date of death due to any cause. Survival time was censored at date of last contact for participants who were still alive or lost to follow-up. Because only 8 participants had documented death while on study, results are reported as 6- and 12-month overall survival probability.
Time frame: baseline to date of death from any cause
| Milestone | Gemcitabine + Paclitaxel |
|---|---|
| Started | 60 |
| Completed | 48 |
| Not completed | 12 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 8 |
| Withdrew: Lost to follow-up | 2 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
| participants | Gemcitabine + Paclitaxel |
|---|---|
| Complete Response (CR) | 2 |
| Partial Response (PR) | 27 |
| Stable Disease (SD) | 20 |
| Progressive Disease (PD) | 7 |
| Early Death from Malignant Disease | 0 |
| Death from Toxicity | 0 |
| Early Death from Other Causes | 0 |
| Unknown | 2 |
Defined as time from enrollment to the date of death due to any cause, measured disease progression, treatment discontinuation for undocumented progression, early treatment discontinuation for toxicity or other reason, or new anticancer treatment started.
| months | Gemcitabine + Paclitaxel |
|---|---|
| Time to Treatment Failure | 4.5 (4.1 to 5.3) |
Defined as the time from enrollment to the date of objective disease progression or death on study, whichever occurs first. Censoring was determined based on US-FDA 2005 draft guidance on clinical endpoints.
| months | Gemcitabine + Paclitaxel |
|---|---|
| Progression-Free Survival | 7.6 (5.8 to 8.8) |
Measured from the time of first documentation of complete response (CR) or partial response (PR), whichever status is first recorded, until the date of objective disease progression or death on study, whichever occurs first, with censoring defined in the same way as for progression-free survival.
| months | Gemcitabine + Paclitaxel |
|---|---|
| Duration of Response | 5.6 (4.4 to 7.6) |
Original outcome was overall survival = time from date of enrollment to date of death due to any cause. Survival time was censored at date of last contact for participants who were still alive or lost to follow-up. Because only 8 participants had documented death while on study, results are reported as 6- and 12-month overall survival probability.
| percent | Gemcitabine + Paclitaxel |
|---|---|
| 6-Month Overall Survival Probability | 97 |
| 12-Month Overall Survival Probability | 87 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine + Paclitaxel | — | — | — |
| Event | Gemcitabine + Paclitaxel |
|---|---|
| Femur fractureInjury, poisoning and procedural complications | 1/60 |
| Event | Gemcitabine + Paclitaxel |
|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 50/60 |
| NeutropeniaBlood and lymphatic system disorders | 46/60 |
| LeukopeniaBlood and lymphatic system disorders | 42/60 |
| MyalgiaMusculoskeletal and connective tissue disorders | 35/60 |
| Peripheral sensory neuropathyNervous system disorders | 28/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/60 |
| FatigueGeneral disorders | 19/60 |
| Alanine aminotransferase increasedInvestigations | 16/60 |
| NauseaGastrointestinal disorders | 13/60 |
| VomitingGastrointestinal disorders | 13/60 |
| Age Continuous(years) | Gemcitabine + Paclitaxel |
|---|---|
| Mean | 46.9 ± 8.96 |
| Sex: Female, Male(Participants) | Gemcitabine + Paclitaxel |
|---|---|
| Female | 60 |
| Male | 0 |
| Region of Enrollment(participants) | Gemcitabine + Paclitaxel |
|---|---|
| China | 60 |
| Disease Stage at Study Entry(participants) | Gemcitabine + Paclitaxel |
|---|---|
| Stage IIIB | 6 |
| Stage IV | 54 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Gemcitabine + Paclitaxel |
|---|---|
| 0 - Fully Active | 30 |
| 1 - Ambulatory, Restricted Strenuous Activity | 30 |
| Menopausal Status(participants) | Gemcitabine + Paclitaxel |
|---|---|
| Pre-Menopausal | 29 |
| Peri-Menopausal | 7 |
| Post Menopausal | 22 |
| Missing | 2 |
| Pathological Diagnosis(participants) | Gemcitabine + Paclitaxel |
|---|---|
| Undifferentiated Breast Carcinoma | 1 |
| Infiltrating Lobular Carcinoma | 0 |
| Infiltrating Ductal Breast Carcinoma | 55 |
| Adenocarcinoma | 3 |
| Comedocarcinoma | 0 |
| Missing | 1 |
| Race/Ethnicity(participants) | Gemcitabine + Paclitaxel |
|---|---|
| East Asian (Chinese) | 60 |
2 further baseline measures are reported on the registry.
The record gives a start of Apr 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Paclitaxel